DiaMedica Therapeutics' (DMAC) Target Price Raised by 37.5% to $11.00 by Craig-Hallum Analyst.

DiaMedica Therapeutics (DMAC) has seen its stock target price raised by Craig-Hallum analyst Chase Knickerbocker from $8.00 to $11.00, a 37.50% increase. The analyst maintains a "Buy" rating on the stock, reflecting confidence in the company's growth potential. Based on one-year price targets, the average target price for DMAC is $9.67, with a high estimate of $11.00 and a low estimate of $8.00.

July 2, 2025

Craig-Hallum analyst Chase Knickerbocker has increased the price target for DiaMedica Therapeutics (DMAC) from $8.00 to $11.00, a 37.50% increase, while maintaining a "Buy" rating on the stock. This adjustment follows the positive interim findings from Part 1a of DiaMedica's Phase 2 trial, which is exploring DM199 as a treatment for preeclampsia [1]. The data reveals significant reductions in both systolic and diastolic blood pressure, with the highest dosage group seeing immediate decreases of 35 mmHg and 15 mmHg respectively within 5 minutes. Although the number of participants was limited, a 24-hour period showed average reductions of 20 mmHg systolic and 10 mmHg diastolic, signaling potential clinical relevance.

The promising results suggest further exploration into Part 1b of the trial and beyond, as indicated by Craig-Hallum. Notably, the evidence also confirms that DM199 does not pass through the placental barrier, which is a significant consideration in its ongoing development.

Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for DiaMedica Therapeutics Inc (DMAC) is $9.67 with a high estimate of $11.00 and a low estimate of $8.00. The average target implies an upside of 145.97% from the current price of $3.93 [2]. More detailed estimate data can be found on the DiaMedica Therapeutics Inc (DMAC) Forecast page.

Based on the consensus recommendation from 3 brokerage firms, DiaMedica Therapeutics Inc's (DMAC) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Positive Points
DiaMedica Therapeutics Inc (DMAC) is making substantial progress in its clinical development programs, particularly in the preeclampsia and stroke areas. The company is close to identifying a target dose for its phase 2 preeclampsia trial, with preliminary top-line results expected between June and July. Enrollment in the stroke program is progressing steadily, with participant enrollment reaching between the 20th and 25th percentile mark. The company has engaged an experienced stroke neurologist to support site engagement and maintain enrollment momentum in the Remedy II trial. DiaMedica Therapeutics Inc (DMAC) has a strong financial position with a total combined cash and investments of $37.3 million as of March 31, 2025, providing a runway into Q3 of 2026 [3].

Negative Points
The company's net cash used in operating activities increased to $7.1 million for the first quarter of 2025, up from $6.7 million in the same period of 2024. Research and development expenses rose significantly to $5.7 million for the three months ended March 31, 2025, compared to $3.7 million for the same period in 2024. General and administrative expenses increased to $2.5 million for the three months ended March 31, 2025, from $2.1 million in the same period of 2024. The company anticipates that R&D expenses will moderately increase in future periods due to the continuation of the Remedy II trial and expansion of the DM 199 clinical development program. Interest income decreased, resulting in a net other income of $443,000 for the three months ended March 31, 2025, compared to $597,000 for the same period in 2024 [4].

References
[1] https://www.ainvest.com/news/diamedica-craig-hallum-maintains-buy-raises-pt-11-8-2507/
[2] https://www.bioworld.com/articles/722267-diamedicas-dm-199-shows-promise-for-serious-pregnancy-disorder?v=preview
[3] https://www.gurufocus.com/news/2987703/diamedica-therapeutics-dmac-sees-price-target-boost-amid-promising-trial-results-dmac-stock-news
[4] https://www.gurufocus.com/news/2987071/analyst-raises-price-target-for-diamedica-therapeutics-dmac-dmac-stock-news